PACS1 Syndrome: Genetic Basis and Therapeutic Paths

PACS1 syndrome is caused by a single-letter change in the PACS1 gene, nearly always the exact same mutation in every diagnosed individual: an arginine-to-tryptophan substitution at position 203 of the protein. Because the mutation arises spontaneously rather than being inherited from a parent, it was only formally described in 2012, and the total number of confirmed cases worldwide still numbers in the low hundreds. Yet the condition has attracted outsized scientific interest, partly because the uniformity of the mutation makes it an unusually clean target for emerging genetic therapies, and partly because recent work in mice has already shown that those therapies can reverse neuronal damage in the lab.

The Mutation Behind the Syndrome

In 2012, researchers studying two unrelated boys with intellectual disability and strikingly similar facial features performed whole-exome sequencing and found the same spontaneous mutation in both: a cytosine-to-thymine change at position 607 in the PACS1 gene, which swaps arginine for tryptophan at amino acid 203 (p.Arg203Trp, commonly shortened to R203W).¹ The mutation is de novo, meaning it is not carried by either parent but instead appears for the first time in the affected child. That explains why the condition does not run in families and why parents with one affected child face an extremely low recurrence risk in future pregnancies.

What makes PACS1 syndrome unusual among rare genetic disorders is how genetically uniform it is. The overwhelming majority of confirmed patients carry the identical R203W substitution. A single case report from Brazil has described a different missense variant in PACS1 (p.Arg315Trp) in a child with a similar clinical picture, broadening the genetic landscape slightly.² But for practical purposes, PACS1 syndrome is essentially a one-mutation disease, which has important implications for treatment design.

What PACS1 Normally Does in the Cell

The PACS1 protein is a sorting director inside cells. It works in the network of membranes that package and route proteins to their correct destinations. Specifically, PACS1 helps keep certain proteins stationed in the trans-Golgi network, the cell’s major distribution hub, by linking those cargo proteins to the clathrin-coated machinery that shuttles them back when they drift away.³ Among the cargo it handles are furin, an enzyme that processes many other proteins, and the mannose-6-phosphate receptor, which routes enzymes to lysosomes.⁴

This sorting role matters everywhere in the body, but it is especially important during brain development, when neurons must move proteins to precise locations along growing axons and dendrites. The R203W mutation does not simply break the protein. Instead, it changes its behavior in a way that causes problems even while the normal copy of the gene is still present on the other chromosome.

Gain of Function, Not Loss

A critical question for any genetic disease is whether the mutation destroys the protein’s function or warps it into doing something new and harmful. For PACS1 syndrome, the evidence increasingly points toward a gain-of-function mechanism, meaning the mutant protein actively does something toxic rather than simply being absent. Zebrafish embryos injected with mutant PACS1 mRNA developed craniofacial defects, while embryos injected with the normal version did not. When the researchers injected equal amounts of normal and mutant mRNA together, the craniofacial problems were substantially rescued, a pattern that initially suggested a dominant-negative effect (the mutant protein interfering with the normal copy).⁵

More recent work has refined the picture. Brain organoids grown from stem cells carrying the R203W mutation showed increased levels of certain proteins compared to controls, while organoids in which PACS1 was deleted entirely looked the same as normal tissue. That pattern is the hallmark of gain of function: removing the gene does nothing abnormal, but the specific mutant version does.⁶ A review of the molecular evidence likewise concluded that a gain-of-function or dominant-negative mechanism is at work, and noted that this makes the mutant protein an attractive drug target: if you can selectively reduce or silence it, the remaining normal copy should be enough.⁷

The HDAC6 Connection

One of the most actionable discoveries about PACS1 syndrome came from mouse studies that identified a specific partner through which the mutant protein causes harm. Researchers found that PACS1 normally interacts with HDAC6, an enzyme that removes chemical tags (acetyl groups) from tubulin, the structural scaffolding inside cells. The R203W mutation strengthens this interaction, causing HDAC6 to become overactive and strip too much acetylation from tubulin.⁸ In neurons, tubulin acetylation helps maintain the microtubule tracks along which organelles and signaling molecules travel. When those tracks are destabilized by excessive stripping, neuronal structure and synaptic communication suffer.

This finding matters because HDAC6 inhibitors already exist and are in clinical development for other conditions. The fact that the R203W mutation funnels much of its damage through a single druggable enzyme gives researchers a potential shortcut: rather than needing to fix the gene itself, blocking its downstream partner might be enough to reduce symptoms.

What PACS1 Syndrome Looks Like Clinically

Children with PACS1 syndrome share a recognizable set of features, though the severity varies. The facial appearance is often the first clue: widely spaced eyes, downward-slanting eyelid openings, a short nose with upturned nostrils, a thin upper lip, and downturned corners of the mouth.⁹ This distinct facial pattern was what initially tipped off the clinicians who first described the syndrome.

Intellectual disability is universal but varies in degree. In a study of 35 confirmed individuals, about 91% walked independently, roughly 72% used speech, and just under half could feed themselves without help.¹⁰ Seizures are common, affecting about half of diagnosed patients. In a separate cohort of 19 patients, seizures responded well to standard anti-seizure medications in most cases.¹¹

Structural abnormalities beyond the face are frequent. In the same 19-patient series, heart defects appeared in roughly half, brain abnormalities in about three-quarters of those imaged, and eye findings in about half. Kidney anomalies and undescended testes in boys also occurred.¹¹ More detailed cardiac assessment in a smaller group found ascending aortic dilation and mitral valve prolapse among the findings, suggesting that heart surveillance should be ongoing, not just a one-time check.¹² Eye involvement can include coloboma (a gap in the structure of the eye), nearsightedness, nystagmus, and strabismus.¹³

The Behavioral Profile and How It Differs from Typical Autism

Autism spectrum disorder or autistic features are reported in a large proportion of individuals with PACS1 syndrome. In one cohort, about 40% had a formal autism diagnosis and another 37% were described as having autistic features without meeting full diagnostic criteria.¹⁰ But a closer look at the pattern of symptoms suggests that the autism seen in PACS1 syndrome has a distinctive signature.

A detailed behavioral study of five children with PACS1 syndrome found that all showed elevated scores for restricted and repetitive behaviors, including hand and finger mannerisms, repetitive interests, and unusual sensory interests. These scores were as high as or higher than those seen in children with non-syndromic autism. However, scores related to social engagement, like joint attention, shared enjoyment, and responsive smiling, were generally lower than in the comparison autism group.¹⁴ In other words, children with PACS1 syndrome tend to have pronounced repetitive behaviors but relatively milder social difficulties compared to the typical autism profile. This dissociation matters for how families and therapists approach intervention. Standard autism therapies heavily weighted toward social skills training may need to be balanced with more emphasis on managing sensory and repetitive behavior challenges.

The same study also noted a consistent pattern of greater inattention than hyperactivity, though none of the children met formal thresholds for an ADHD diagnosis.¹⁴ This is the kind of nuance that can get lost when a child receives a broad autism label without the underlying genetic cause being identified.

Getting to a Diagnosis

Because PACS1 syndrome was only described in 2012 and remains rare, many clinicians have never encountered it. Diagnosis typically happens when a child with unexplained developmental delay and the characteristic facial features undergoes genetic testing, usually whole-exome sequencing or a gene panel that includes PACS1. Before those tests became affordable and widely available, children with the condition were often given non-specific diagnoses like “intellectual disability of unknown cause” or “syndromic autism.”

The median age at diagnosis in one cohort was 8 years, and roughly half the group was female, countering an early impression (based on the two originally described boys) that the syndrome predominantly affects males.¹⁰ As awareness grows and genetic testing becomes more routine in the workup of developmental delay, the age at diagnosis is expected to drop, which matters for any future treatments that might work better when started early.

Research Models and What They Have Revealed

The path from understanding a mutation to treating a disease runs through lab models, and PACS1 syndrome now has several. The earliest work used zebrafish, where injecting mutant PACS1 mRNA into embryos produced craniofacial defects that mirrored what is seen in patients, establishing the mutation’s direct role in disrupting the migration of cranial neural-crest cells.⁵

A mouse model carrying the equivalent R203W mutation has proven especially valuable. These mice show neuronal abnormalities and problems with synaptic transmission that parallel the intellectual disability and seizures seen in patients, making them a credible platform for testing treatments.⁸ Researchers have also generated cortical organoids, miniature brain-like structures grown from patient-derived stem cells, to study how the mutation affects human brain development at a cellular level. These organoids have revealed altered gene activity and changes in the balance between excitatory and inhibitory neurons.¹⁵ Additional proteomic work on organoids is mapping the broader set of proteins disrupted by the mutation, which could reveal more drug targets.¹⁶

Even the roundworm C. elegans has contributed. The PACS1 protein’s key functional region is highly conserved across species: the worm version shares about 45% identical amino acids with the human version in the region where the R203W mutation sits. When researchers introduced the equivalent mutation in worms, the mutant protein was mislocalized within cells, offering a simple system for testing whether drugs can correct protein behavior.¹⁷

Therapeutic Strategies Under Exploration

The uniformity of the mutation and the gain-of-function mechanism together make PACS1 syndrome an appealing candidate for targeted therapy. Several strategies are being explored, each attacking the problem at a different level.

Antisense oligonucleotides (ASOs): These are short stretches of synthetic nucleic acid designed to bind the messenger RNA from the mutant copy of PACS1 and flag it for destruction before it can be translated into protein. In PACS1 syndrome mice, treatment with ASOs targeting PACS1 restored neuronal structure and synaptic transmission.¹⁸ ASOs are already approved for other neurological conditions, so the delivery infrastructure for getting them into the brain (typically via spinal injection) exists.
HDAC6 inhibitors: Because the R203W mutation exerts much of its damage by over-activating HDAC6, blocking that enzyme directly is another route. ASOs targeting HDAC6 also corrected neuronal deficits in the same mouse study, demonstrating that you do not necessarily have to target PACS1 itself.⁸ Small-molecule HDAC6 inhibitors are in clinical trials for other diseases, which could speed repurposing.
PROTACs: Proteolysis-targeting chimeras are a newer class of drug designed to physically escort a specific protein to the cell’s disposal machinery for degradation. In theory, a PROTAC could be engineered to selectively grab the mutant PACS1 protein and mark it for destruction while leaving the normal copy alone.¹⁹ This approach is still conceptual for PACS1 syndrome, but the PROTAC platform has advanced rapidly in oncology.
Small molecules targeting the mutant protein directly: If the R203W substitution creates a binding pocket or surface that differs from the normal protein, a small molecule could be designed to block it. This is the most traditional drug-design approach but faces the challenge that the R203W change is subtle, altering a single amino acid, making selective targeting difficult.

All of these remain preclinical. No human trials are underway for PACS1 syndrome as of mid-2025. The mouse ASO results are the most advanced proof of concept, and the natural history data being collected by patient advocacy groups, including developmental milestones and seizure frequency, are being organized specifically to support future trial readiness.¹⁰

Why a Single Mutation Makes Trial Design Easier and Harder

Having virtually every patient carry the same mutation is a rare luxury in genetic disease. It means a single ASO sequence or a single PROTAC design could theoretically treat the entire patient population, and preclinical models are directly relevant to every patient rather than only a subset. There is no need to develop different therapies for different mutation types, as is necessary in conditions like cystic fibrosis, where hundreds of variants exist.

The challenge is on the other side of the equation: the patient population is tiny. With confirmed cases worldwide still in the low hundreds, recruiting enough participants for a statistically powered clinical trial is difficult. Rare-disease regulatory pathways exist precisely for this situation, allowing smaller trials with adaptive designs, but meaningful efficacy endpoints still need to be defined. That is partly why recent natural history studies have focused on documenting which skills patients have at which ages: walking independently, using speech, achieving basic academic skills. These benchmarks provide the outcome measures against which a future drug trial can demonstrate improvement.

Conservation Across Species

One reason the R203W mutation is so consistently damaging is that the region of the protein where it occurs, called the furin-binding region, is ancient and deeply conserved. In the roundworm C. elegans, which diverged from humans over 500 million years ago, the equivalent stretch of the PACS1 protein is about 70% similar at the amino acid level to the human version.¹⁷ When the worm version of this region is deleted, the protein becomes unstable, suggesting the region is not just important for binding cargo but for the protein’s very survival inside the cell. That level of conservation explains why a single amino acid swap at this position is not tolerated: evolution has locked this site into place because changes here reliably cause problems, and the R203W substitution is harmful enough that it never becomes heritable (affected individuals very rarely have children, and the mutation arises de novo each time).

Organ Surveillance After Diagnosis

Because PACS1 syndrome can affect multiple organ systems, diagnosis should trigger a structured set of evaluations. The high prevalence of heart defects, including structural problems in early life and connective-tissue findings like aortic dilation later, argues for baseline echocardiography with periodic follow-up.¹² Eye abnormalities ranging from structural colobomas to refractive errors and retinal findings warrant early ophthalmologic assessment.¹³ Brain MRI, renal ultrasound, and a thorough seizure history round out the initial workup. Seizures, when they occur, generally respond to standard medications, which is one of the more reassuring aspects of the clinical picture.¹¹

For families, getting the genetic diagnosis itself often changes management more than any single specialist visit. It connects them to a community of other affected families, gives clinicians a checklist of what to monitor, and makes the child eligible for emerging research studies. It also ends the diagnostic odyssey that many families endure for years, bouncing between specialists who each see only one piece of the picture.

1
The American Journal of Human Genetics. Recurrent De Novo Mutations in PACS1 Cause Defective Cranial-Neural-Crest Migration and Define a Recognizable Intellectual-Disability Syndrome
2
Cureus. A Novel PACS1 Variant Associated With Schuurs-Hoeijmakers Syndrome Phenotype in an Indigenous Descendant in Brazil: A Case Report
3
PubMed. PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization
4
PubMed Central. The phosphorylation state of an autoregulatory domain controls PACS-1-directed protein traffic
5
American Journal of Human Genetics. Recurrent De Novo Mutations in PACS1 Cause Defective Cranial-Neural-Crest Migration and Define a Recognizable Intellectual-Disability Syndrome
6
bioRxiv. A gain-of-function recurrent missense variant leads to a GABAergic/glutamatergic imbalance in a forebrain organoid model of PACS1 syndrome
7
PubMed Central. Molecular Basis of the Schuurs-Hoeijmakers Syndrome: What We Know about the Gene and the PACS-1 Protein and Novel Therapeutic Approaches
8
Nature Communications. Neural deficits in a mouse model of PACS1 syndrome are corrected with PACS1- or HDAC6-targeting therapy
9
Brain and Development Case Reports. Clinical characteristics for early diagnosis of PACS1 neurodevelopmental disorder: Two case reports
10
PubMed Central. PACS1-Neurodevelopmental disorder: clinical features and trial readiness
11
PubMed. Clinical delineation of the PACS1-related syndrome–Report on 19 patients
12
PubMed Central. Heart Disease Characterization and Myocardial Strain Analysis in Patients with PACS1 Neurodevelopmental Disorder
13
PubMed. A case report of retinal dystrophy in patients with PACS1 syndrome
14
PubMed Central. Phenotypic Characterization of Five Children With PACS1-NDD: Longitudinal Insights Into Development, Behavior, and Brain
15
Nature Communications. iPSC-derived models of PACS1 syndrome reveal transcriptional and functional deficits in neuron activity
16
PubMed Central. PACS1 syndrome variant alters proteomic landscape of developing cortical organoids
17
Genetics. PACS-1 variant protein is aberrantly localized in Caenorhabditis elegans model of PACS1/PACS2 syndromes
18
PubMed Central. RNA-targeted therapy corrects neuronal deficits in PACS1 syndrome mice
19
Cell Press (Trends in Genetics). Bridging the gap in PACS1 syndrome research